PURPOSE: To detect alterations in DNA damage repair (DDR) genes, measure homologous recombination deficiency (HRD), and correlate these findings with clinical outcome in patients with leiomyosarcoma (LMS). PATIENTS AND METHODS: Patients with LMS treated at Memorial Sloan Kettering (MSK) Cancer Center who consented to prospective targeted next-generation sequencing with MSK-IMPACT were screened for oncogenic somatic variants in one of 33 DDR genes; where feasible, an experimental HRD score was calculated from IMPACT data. Progression-free survival (PFS) and overall survival (OS) were estimated after stratifying patients by DDR gene alteration status and HRD score. RESULTS: Of 211 patients with LMS, 20% had an oncogenic DDR gene alteration. Univariable analysis of PFS in 117 patients who received standard frontline chemotherapy in the metastatic setting found that an altered homologous recombination pathway gene was significantly associated with shorter PFS (hazard ratio [HR], 1.79; 95% CI, 1.04 to 3.07; P = .035). Non-BRCA homologous recombination gene alteration was associated with shorter PFS (HR, 2.61; 95% CI, 1.35 to 5.04; P = .004) compared with BRCA-altered and wild-type homologous recombination genes. Univariable analysis of OS from diagnosis in the entire cohort of 211 patients found that age, tumor size, number of metastatic sites, localized disease, and non-BRCA homologous recombination gene alteration were significantly associated with OS. On multivariable analysis, non-BRCA homologous recombination pathway gene alteration remained significant (HR, 4.91; 95% CI, 2.47 to 9.76; P < .001). High HRD score was not associated with a different PFS or OS. CONCLUSION: Patients with LMS with homologous recombination pathway gene alterations have poor clinical outcomes, particularly those with non-BRCA gene alterations. HRD score calculated from a targeted exome panel did not discern disparate clinical outcomes.
PURPOSE: To detect alterations in DNA damage repair (DDR) genes, measure homologous recombination deficiency (HRD), and correlate these findings with clinical outcome in patients with leiomyosarcoma (LMS). PATIENTS AND METHODS: Patients with LMS treated at Memorial Sloan Kettering (MSK) Cancer Center who consented to prospective targeted next-generation sequencing with MSK-IMPACT were screened for oncogenic somatic variants in one of 33 DDR genes; where feasible, an experimental HRD score was calculated from IMPACT data. Progression-free survival (PFS) and overall survival (OS) were estimated after stratifying patients by DDR gene alteration status and HRD score. RESULTS: Of 211 patients with LMS, 20% had an oncogenic DDR gene alteration. Univariable analysis of PFS in 117 patients who received standard frontline chemotherapy in the metastatic setting found that an altered homologous recombination pathway gene was significantly associated with shorter PFS (hazard ratio [HR], 1.79; 95% CI, 1.04 to 3.07; P = .035). Non-BRCA homologous recombination gene alteration was associated with shorter PFS (HR, 2.61; 95% CI, 1.35 to 5.04; P = .004) compared with BRCA-altered and wild-type homologous recombination genes. Univariable analysis of OS from diagnosis in the entire cohort of 211 patients found that age, tumor size, number of metastatic sites, localized disease, and non-BRCA homologous recombination gene alteration were significantly associated with OS. On multivariable analysis, non-BRCA homologous recombination pathway gene alteration remained significant (HR, 4.91; 95% CI, 2.47 to 9.76; P < .001). High HRD score was not associated with a different PFS or OS. CONCLUSION:Patients with LMS with homologous recombination pathway gene alterations have poor clinical outcomes, particularly those with non-BRCA gene alterations. HRD score calculated from a targeted exome panel did not discern disparate clinical outcomes.
Authors: Min Yuen Teo; Richard M Bambury; Emily C Zabor; Emmet Jordan; Hikmat Al-Ahmadie; Mariel E Boyd; Nancy Bouvier; Stephanie A Mullane; Eugene K Cha; Nitin Roper; Irina Ostrovnaya; David M Hyman; Bernard H Bochner; Maria E Arcila; David B Solit; Michael F Berger; Dean F Bajorin; Joaquim Bellmunt; Gopakumar Iyer; Jonathan E Rosenberg Journal: Clin Cancer Res Date: 2017-01-30 Impact factor: 12.531
Authors: Nathan D Seligson; Esko A Kautto; Edward N Passen; Colin Stets; Amanda E Toland; Sherri Z Millis; Christian F Meyer; John L Hays; James L Chen Journal: Oncologist Date: 2018-12-12
Authors: Mansoor R Mirza; Bradley J Monk; Jørn Herrstedt; Amit M Oza; Sven Mahner; Andrés Redondo; Michel Fabbro; Jonathan A Ledermann; Domenica Lorusso; Ignace Vergote; Noa E Ben-Baruch; Christian Marth; Radosław Mądry; René D Christensen; Jonathan S Berek; Anne Dørum; Anna V Tinker; Andreas du Bois; Antonio González-Martín; Philippe Follana; Benedict Benigno; Per Rosenberg; Lucy Gilbert; Bobbie J Rimel; Joseph Buscema; John P Balser; Shefali Agarwal; Ursula A Matulonis Journal: N Engl J Med Date: 2016-10-07 Impact factor: 91.245
Authors: Rebecca A Gladdy; Li-Xuan Qin; Nicole Moraco; Narasimhan P Agaram; Murray F Brennan; Samuel Singer Journal: Ann Surg Oncol Date: 2013-01-25 Impact factor: 5.344
Authors: Andrea M Marquard; Aron C Eklund; Tejal Joshi; Marcin Krzystanek; Francesco Favero; Zhigang C Wang; Andrea L Richardson; Daniel P Silver; Zoltan Szallasi; Nicolai J Birkbak Journal: Biomark Res Date: 2015-05-01
Authors: Theo A Knijnenburg; Linghua Wang; Michael T Zimmermann; Nyasha Chambwe; Galen F Gao; Andrew D Cherniack; Huihui Fan; Hui Shen; Gregory P Way; Casey S Greene; Yuexin Liu; Rehan Akbani; Bin Feng; Lawrence A Donehower; Chase Miller; Yang Shen; Mostafa Karimi; Haoran Chen; Pora Kim; Peilin Jia; Eve Shinbrot; Shaojun Zhang; Jianfang Liu; Hai Hu; Matthew H Bailey; Christina Yau; Denise Wolf; Zhongming Zhao; John N Weinstein; Lei Li; Li Ding; Gordon B Mills; Peter W Laird; David A Wheeler; Ilya Shmulevich; Raymond J Monnat; Yonghong Xiao; Chen Wang Journal: Cell Rep Date: 2018-04-03 Impact factor: 9.423
Authors: Benjamin A Nacev; Francisco Sanchez-Vega; Shaleigh A Smith; Cristina R Antonescu; Evan Rosenbaum; Hongyu Shi; Cerise Tang; Nicholas D Socci; Satshil Rana; Rodrigo Gularte-Mérida; Ahmet Zehir; Mrinal M Gounder; Timothy G Bowler; Anisha Luthra; Bhumika Jadeja; Azusa Okada; Jonathan A Strong; Jake Stoller; Jason E Chan; Ping Chi; Sandra P D'Angelo; Mark A Dickson; Ciara M Kelly; Mary Louise Keohan; Sujana Movva; Katherine Thornton; Paul A Meyers; Leonard H Wexler; Emily K Slotkin; Julia L Glade Bender; Neerav N Shukla; Martee L Hensley; John H Healey; Michael P La Quaglia; Kaled M Alektiar; Aimee M Crago; Sam S Yoon; Brian R Untch; Sarah Chiang; Narasimhan P Agaram; Meera R Hameed; Michael F Berger; David B Solit; Nikolaus Schultz; Marc Ladanyi; Samuel Singer; William D Tap Journal: Nat Commun Date: 2022-06-15 Impact factor: 17.694
Authors: Mrinal M Gounder; Narasimhan P Agaram; Sally E Trabucco; Victoria Robinson; Richard A Ferraro; Sherri Z Millis; Anita Krishnan; Jessica Lee; Steven Attia; Wassim Abida; Alexander Drilon; Ping Chi; Sandra P D' Angelo; Mark A Dickson; Mary Lou Keohan; Ciara M Kelly; Mark Agulnik; Sant P Chawla; Edwin Choy; Rashmi Chugh; Christian F Meyer; Parvathi A Myer; Jessica L Moore; Ross A Okimoto; Raphael E Pollock; Vinod Ravi; Arun S Singh; Neeta Somaiah; Andrew J Wagner; John H Healey; Garrett M Frampton; Jeffrey M Venstrom; Jeffrey S Ross; Marc Ladanyi; Samuel Singer; Murray F Brennan; Gary K Schwartz; Alexander J Lazar; David M Thomas; Robert G Maki; William D Tap; Siraj M Ali; Dexter X Jin Journal: Nat Commun Date: 2022-06-15 Impact factor: 17.694
Authors: Evan Rosenbaum; Cristina R Antonescu; Shaleigh Smith; Martina Bradic; Daniel Kashani; Allison L Richards; Mark Donoghue; Ciara M Kelly; Benjamin Nacev; Jason E Chan; Ping Chi; Mark A Dickson; Mary L Keohan; Mrinal M Gounder; Sujana Movva; Viswatej Avutu; Katherine Thornton; Ahmet Zehir; Anita S Bowman; Samuel Singer; William Tap; Sandra D'Angelo Journal: J Immunother Cancer Date: 2022-04 Impact factor: 12.469
Authors: Nathan D Seligson; Joy Tang; Dexter X Jin; Monica P Bennett; Julia A Elvin; Kiley Graim; John L Hays; Sherri Z Millis; Wayne O Miles; James L Chen Journal: NPJ Precis Oncol Date: 2022-04-25
Authors: Bernd Kasper; Lorenzo D'Ambrosio; Elizabeth J Davis; Matthew Ingham; Javier Martin Broto; Jonathan C Trent; Winan J van Houdt; Brian A Van Tine Journal: Curr Treat Options Oncol Date: 2022-03-11